Analyst upgrades, downgrades and initiations: AKAM, MRVL, THRX, DELL, CRNT, TRV, AEIS ...

Eric Buscemi — Thu, 05 Feb 2009 11:45:00 EST

Analyst upgrades:

Citigroup upgraded shares of Akamai (NASDAQ: AKAM) to Buy from Hold following the company's Q4 results as they believe fundamentals are stabilizing. The firm raised their target price to $22 from $12.
Baird upgraded Theravance (NASDAQ: THRX) to Outperform from Neutral. The firm said the company looks poised to realize the two-product success necessary to drive profitability, and Horizon will likely play a role in succeeding $7B+ Advair. Note that last night Theravance/Glaxo (GSK) reported positive results for Horizon.
RBC Capital said Aeterna Zentaris (NASDAQ: AEZS) is on the cusp of a Cetrorelix deal and has turned more positive on shares. Shares were upgraded to Outperform from Sector Perform.
Marvell Tech (NASDAQ: MRVL) was upgraded to Buy from Neutral at Goldman and added to the firm's Conviction Buy List.
Sangamo BioSciences (NASDAQ: SGMO) was raised to Buy from Neutral at Merriman.
Arthur J. Gallagher (NYSE: AJG) was upgraded at Piper Jaffray to Buy from Neutral.

Analyst upgrades, downgrades and initiations: RBS, COH, BJ, QCOM, SNDK, MAT, MGM ...

Eric Buscemi — Tue, 03 Feb 2009 10:55:00 EST

Analyst upgrades:

HSBC upgraded Royal Bank of Scotland (NYSE: RBS) to Overweight from Neutral as it believes the risk of immediate nationalization has been removed.
JP Morgan upgraded DTS Inc (NASDAQ: DTSI) to Overweight from Neutral to reflect accretion from the Neural acquisition and its expectation the company can generate strong cash flow during the downturn. The firm raised its target to $18.
Cowen upgraded Coach (NYSE: COH) to Outperform from Neutral citing the recent sell-off in shares.
BJ's Wholesale (NYSE: BJ) was upgraded to Buy from Neutral at UBS.
First Horizon (NYSE: FHN) was upgraded to Overweight from Equal Weight at Morgan Stanley.
Spartech (NYSE: SEH) was raised to Hold from Underweight at KeyBanc.